The synergistic proapoptotic interaction of MCL1 inhibition and TKI treatment in CML cells depends on TKI-mediated BCR-ABL1 inhibition and is not generated by TKI-related off-target mechanisms. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.